¡Ya estamos en ! Descubre más

NeuBase Therapeutics, Inc. Common Stock

NBSE

Capitalización de mercado USD 1.42 M

Excluida de cotización

NBSE dejó de cotizar en bolsa el 10 de mayo de 2024.

Volver al ranking

Acerca de: NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Empleados: 37

Salud Fabricantes de medicamentos - General

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 0%

Negativo 0%

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) in a timely manner.

NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?

NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™